0000816956-26-000053
SEC filingQ1 revenue dipped 1.3% to $317.0M amid strategic portfolio shifts, but gross margin expansion to 57.9% and operating leverage drove operating income up 59.3% to $25.4M, tripling net income to $13.8M.
CONMED Corporation reported Q1 FY2026 results reflecting strategic portfolio optimization amid a challenging business environment marked by higher manufacturing costs and supply chain pressures. Revenue of $317.0 million declined 1.3% from $321.3 million in the prior-year quarter. This topline moderation occurred as the Company executed on key business drivers, including the termination of its distribution agreement with W.L. Gore, which unlocked significant margin benefits.
Net income tripled to $13.8 million from $6.0 million, with diluted EPS rising 136.8% to $0.45. The earnings acceleration was amplified by a decrease in interest expense, driven by lower weighted average borrowings and interest rates during the quarter. This reflects proactive balance sheet management, reducing the cost of capital amid ongoing liquidity needs for capital investments, working capital, and debt service under the senior credit agreement.